secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioCardia, Inc. (BCDA)
CIK:        0000925741
Form:       8-K
Filed at:   2025-04-15T23:59:59+00:00
Accession:  0001437749-25-011992
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCardia CardiALLO heart failure trial passes DSMB review; no safety issues
----------------------------------------------------------------------------

- DSMB recommends study continue as designed after 30-day safety review of 20M-cell dosing cohort.
- No treatment-emergent major adverse cardiac events or immune reactions observed.
- Company plans to enroll 39 participants in the US for Phase 1/2 CardiALLO-HF trial.
- CEO cites potential for nondilutive funding and partnering, and future pivotal trial in USA, Japan.
- High-dose arm targets patients with active inflammation, at least 2x effective dose of prior MSC studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/925741/000143774925011992/0001437749-25-011992-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/925741/000143774925011992/bcda20250415_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-011992

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer